Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

BACKGROUND: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hormone receptor-positive (HR+), human epidermal grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535465/
https://www.ncbi.nlm.nih.gov/pubmed/36206609
http://dx.doi.org/10.1016/j.breast.2022.09.006

Ejemplares similares

Ejemplares similares